US equities
|
MU
$896.07
▼-0.98%
SPCX
$147.79
▼-0.11%
NVDA
$216.47
▼-0.29%
AAPL
$339.50
▼-1.00%
TSLA
$373.71
▲+1.54%
META
$694.25
▼-1.59%
AMZN
$262.63
▲+0.07%
SNDK
$1,365.38
▼-0.42%
MU
$896.07
▼-0.98%
SPCX
$147.79
▼-0.11%
NVDA
$216.47
▼-0.29%
AAPL
$339.50
▼-1.00%
TSLA
$373.71
▲+1.54%
META
$694.25
▼-1.59%
AMZN
$262.63
▲+0.07%
SNDK
$1,365.38
▼-0.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Teva Pharmaceutical Industries Limited
< Previous
1
2
3
4
5
Next >
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
July 25, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
July 18, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
July 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
June 28, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
June 25, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
June 24, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
May 29, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
May 15, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Present at the 2024 Bank of America Healthcare Conference
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 11, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
April 09, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
April 06, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
April 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
April 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
CG
TEVA
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
February 26, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
ALVO
TEVA
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
February 20, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Reports Growth in Fourth Quarter and Full Year 2023
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
January 31, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
January 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Tickers
TEVA
< Previous
1
2
3
4
5
Next >
